Epidemiologic studies evaluating associations between biomarkers of exposure to short-lived chemicals and health endpoints in humans face special challenges. Perhaps the most critical challenges are the need to determine the type and optimal number of samples, and the proper timing of specimen collection. Further, as many short-lived chemicals are ubiquitous in the environment, utmost care is required to avoid sample contamination. A separate set of challenges is associated with appropriate interpretation and reporting of results from multiple simultaneous analyses, which are becoming increasingly feasible. The Biomonitoring, Environmental Epidemiology, and Short-Lived Chemicals (BEES-C) instrument is specifically designed to evaluate the quality of epidemiologic studies that measure biomarkers of chemicals with short physiologic half-lives. The instrument provides systematic guidance for evaluating 14 different aspects of study quality divided into three broad categories: 1) biomarker selection and measurement, 2) strategy and execution of exposure assessment, and 3) general considerations of study design and reporting. We evaluated the utility of the BEES-C instrument using epidemiologic studies of exposure to bisphenol A and its association with neurodevelopmental and respiratory health indicators. Each BEES-C element was assessed with respect to needed modifications and concordance among reviewers using professional, scientific judgment. Based on this first use of the BEES-C instrument, we found that most of its elements were effective in comparing the quality of available studies, with reviews generally concordant and justifications consistent. However, we note that certain elements would be improved with slight adjustments and that one of the elements appeared redundant and should be removed.
Introduction
A weight of evidence (WOE) assessmentmore recently referred to as 'evidence integration' (NRC, 2014)is a "collective evaluation of all pertinent information so that the full impact of biological plausibility and coherence is adequately considered" (USEPA, 1996) . Although epidemiologic research should play a critical role in WOE assessments for human health, reliance on such human research is often hindered by a general lack of methodological harmonization across studies and by limitations of studies in terms of the quality of the exposure assessment and/or issues related to general epidemiologic study design (Gallagher and Meliker, 2010; González-Alzaga et al., 2014; Goodman et al., 2014; LaKind et al., 2014a; LaKind et al., submitted for publication; Schoeman et al., 2009; USEPA, 2013) . Methodological harmonization refers to a body of literature in which studies have built on past research using approaches and study design elements that are sufficiently concordant for conducting meta-analyses or interpreting data from systematic reviews. The importance of this issue has been addressed previously (Goodman et al., 2010; LaKind et al., submitted for publication; Youngstrom et al., 2011) . Here we focus on study quality, which must be evaluated as part of any complete and transparent WOE assessment (LaKind et al., 2014a,b; Thayer et al., 2014) . While professional judgment is unavoidable in any evaluation of study quality, the use of a systematic and transparent set of guidelines may ensure a more Environment International 80 (2015) standardized and reproducible process (Bossuyt et al., 2004; Little et al., 2009; Moher et al., 2001; Owens et al., 2010; Vandenbroucke et al., 2007; Whiting et al., 2003; Youngstrom et al., 2011) . The Biomonitoring, Environmental Epidemiology, and Short-Lived Chemicals (BEES-C) instrument was developed for evaluating quality of human studies that rely on biomarkers of chemicals with short physiologic half-lives (LaKind et al., 2014b) . The BEES-C instrument provides systematic guidance for evaluating study quality for elements including: (i) biomarker selection and measurement, (ii) exposure-related study design, and (iii) data interpretation taking into account multiple factors that may modify exposures and effects. The BEES-C instrument allows for comparative quality assessments of environmental epidemiologic research and aids researchers in manuscript review and in the development of new study grant applications. The BEES-C instrument can assist in the systematic assessment of studies of short-lived chemicals in humans and can be used to identify areas of strength and weakness in this literature.
BEES-C provides a method for conducting a systematic comparative assessment of study quality (using a three-tier system, with Tier 1 indicating the highest quality), intentionally excluding an option for numeric scoring during the process. This approach was taken to address the problem of how to score a study that is generally of high quality but has not addressed a key issue(s) that reduces overall confidence in the study results (e.g., sample contamination); this issue would be masked by a high numeric "score" (LaKind et al., 2014b) . Further, it is essential to recognize that most, if not all, studies will have some elements that would fall into a lower tier, as no single study is expected to fulfill all of the quality requirements. A systematic evaluation of study quality can provide the reviewer with an understanding of the relative robustness of results and conclusions and therefore the applicability of the study results for their proposed use.
In this paper, we evaluate the utility of the previously published BEES-C instrument when applied to the epidemiologic studies on the associations of measured markers of BPA exposure with neurodevelopmental and respiratory health endpoints (LaKind et al., 2014b) . We focused on BPA and its relation to neurodevelopmental and respiratory health endpoints because these bodies of literature met two criteria: (i) a sufficient, but not excessive, body of literature (approximately 5-10 studies) that allows testing and refinement of BEES-C within a reasonable scope of work, and (ii) literature in which individual studies were based on different data sources. Both of these criteria allow us to focus on the utility of the BEES-C instrument and to assess whether modifications are needed. In addition, BPA has been the subject of intense scientific research. A recent systematic review of the epidemiology research on BPA and other health outcomes including diabetes and heart disease identified several exposure and study design issues that severely limit our ability to use the literature for a WOE assessment (LaKind et al., 2014a (LaKind et al., , 2014b . The main shortcomings of the existing body of literature included the predominance of cross-sectional studies and poor exposure characterization. In this current publication, we are specifically interested in examining the BPA literature on other health outcomes to assess whether similar study quality limitations are present. However, this research is not a summary of the evidence on health outcomes associated with BPA exposure. Rather, it AOP = adverse outcome pathway; ECD = electron capture detector; FID = flame ionization detector; FP:FN = false positive:false negative; GC = gas chromatography; ICC = intraclass correlation; MS = mass spectrometry. represents a practical application of the previously proposed instrument aimed at assessing study quality.
For each element of the instrument, we provided input regarding needed modifications of instructions or criteria for tier assignment. We also examined concordance and discordance among reviews.
Methods

Identification and selection of studies
Electronic data sources (PubMed and Embase) were used to conduct the initial literature search. Using keywords "BPA", "bisphenol A", Table 3 BEES-C assessment of Braun et al. (2009) (diagonal line through cell indicates element not assessed by that reviewer).
"neurodevelopment", "humans", "behavior", "asthma", "respiratory", "lung function", and "epidemiology" as well as various combinations of these keywords, we selected articles that investigated neurodevelopmental and respiratory health effects associated with BPA exposures in humans. Secondary references of retrieved articles were reviewed to identify publications not captured by the electronic search.
The criteria for inclusion into the review were as follows:
1. Studies of human populations with individual BPA and/or metabolites measured in biological samples. 2. Outcomes of interest that fall into three broad categories: a. Studies of neurodevelopment using a variety of clinical tests and questionnaires. b. Self-reported respiratory complaints and symptoms of respiratory disease. c. Biomarkers of atopy, airway status and lung function.
3. Publication included complete description of the study (e.g., abstractonly publications were excluded). 4. Publication appeared in English prior to July 2014 (end of literature search).
Literature review
Each study that met the inclusion criteria was examined independently by the authors of this paper. Information extracted from each study for the purposes of this review (Tables 1 and A.1) included:
1. Description of the study population: size, composition, source, and location. 2. Study design: cohort, cross-sectional, case-control or other.
3. BPA exposure categorization: type of specimen, biomarker measured, number of samples, and the type of variable (e.g., ordinal, binary or continuous) used in the analysis. 4. Endpoints of interest (see inclusion criteria). 5. Statistical approach and covariates included in the model.
Assessment of individual study quality
Co-authors of this paper independently reviewed each retrieved study using the BEES-C instrument, which is organized according to aspects of study design (rows) and evaluative tiers (columns) ( Table 2) . For each study, critical aspects were assessed row by row and the appropriate cell color-coded; Tier 1 indicates the highest quality. Because professional judgment is unavoidable and transparency in the process is essential, a final column in the table is used to provide justification for the decision regarding tier selection for each study element. The reasons for discrepancies across reviewers for a given element were assessed and where necessary, recommendations for modifications to an element were given. Reviewers were offered the opportunity to discuss tiering results with each other prior to finalizing their evaluations. Reviewers were also given the opportunity to refrain from scoring any given element.
Although study size and statistical power constitute an import attribute of any study, we did not include this as a separate element in the instrument. Statistical power can be improved by conducting a metaanalysis of several small studies. If, however, available studies are at risk for systematic error (bias) a meta-analysis would be of little help. As noted in the most recent edition of The Cochrane Collaboration Handbook "If bias is present in each (or some) of the individual studies, meta-analysis will simply compound the errors, and produce a wrong result that may be interpreted as having more credibility" (Higgins NA = not applicable. and Green, 2011) . For this reason, the BEES-C instrument was primarily designed to assess possible systematic error (bias) across studies.
Results
Synopsis of neurodevelopmental literature
Seven studies of BPA and neurodevelopment were identified in the literature ( Table 1) . Three of the seven publications were studies of a mother/infant cohort in the Health Outcomes and Measures of the Environment (HOME) Study, in Ohio, US (Braun et al., 2009 (Braun et al., , 2011 Yolton et al., 2011) . Two other studies focused on New York City-based mother/infant cohorts: the Mount Sinai Children's Environmental Health study (Miodovnik et al., 2011) and the Columbia Center for Children's Environmental Health cohort (Perera et al., 2012) . The sixth study was the longitudinal CHAMACOS (Center for the Health Assessment of Mothers and Children of Salinas) birth cohort from California (Harley et al., 2013) . The seventh publication was a school-based crosssectional study of children ages 8-11 years from five (urban, industrial or rural) regions in Korea (Hong et al., 2013) .
The studies used different assessment tools to evaluate neurodevelopment in different age groups. In the HOME cohort, children were examined at 5 weeks of age using the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS), at 2 years of age using the Behavioral Assessment System for Children (BASC-2) Parent Rating Scale for pre-schoolers, and at 3 years of age using the Behavioral Assessment System for Children (BASC-2) and the Behavior Rating Inventory of Executive Function-Preschool (BRIEF-P). In the Mount Sinai study, 7-to 9-year old children were assessed with the Social Responsiveness Scale. In the Columbia study, children 3-5 years of age were examined with the Child Behavior Checklist (CBCL). The CBCL was also used to evaluate the Korean cohort of children ages 8-11 years; in addition, learning disabilities were assessed with the Leaning Disability Evaluation Scale, parent-rated (LDES) and IQ and neurobehavior were examined using the abbreviated form of the Korean Educational Development Institute's Wechsler Intelligence Scales for Children (KEDI-WISC) (Hong et al., 2013) . The children in the CHAMACOS cohort were evaluated by the BASC-2 Parent Rating Scale administered to the mother and the Conner's ADHA/DSM-IV Scales self-administered by the child's teacher (Harley et al., 2013) . At 9 years of age, the children were further assessed with the Connors' Continuous Performance Test (CPT) (Harley et al., 2013) .
All studies examined total BPA concentrations (i.e., free BPA plus conjugated BPA) in urine, but measured BPA at different ages and adjusted BPA levels for creatinine or specific gravity using different approaches. In the HOME study, maternal spot urine samples were collected and analyzed for BPA at~16 and 26 weeks of gestation and at birth; for children, spot samples were collected and measured at 1, 2 and 3 years of age. Two of the studies (Braun et al., 2009 (Braun et al., , 2011 adjusted urinary BPA for creatinine, while Yolton et al. (2011) used unadjusted urinary BPA with creatinine levels included in the model as a covariate. For the Mount Sinai study, one maternal spot urine sample was collected between 25 and 40 weeks of gestation and levels were creatinineadjusted (Miodovnik et al., 2011) . In the Columbia Center study, specific gravity-adjusted BPA was measured in one maternal spot urine sample taken at 24-40 weeks gestation and in one spot urine sample from children 3-4 years of age (Perera et al., 2012) . For the CHAMACOS cohort, two spot urine samples were collected from mothers during pregnancy (mean gestational age of approximately 13 and 26 weeks) and from children at 5 years of age, with maternal BPA measures adjusted using specific gravity and children's measures creatinine-adjusted (Harley et al., 2013) . In the Korean cohort, one urine sample was collected from each child in the morning at school and BPA levels were creatinine-adjusted (Hong et al., 2013) . NA = not applicable. 
Synopsis of respiratory health literature
The literature search identified five studies on BPA and respiratory health (Table A .1). Three of the publications were prospective birth cohort studies of mother/child pairs. One of these cohorts was comprised of participants in the Columbia Center for Children's Environmental Health study (Donohue et al., 2013) and the other two included participants in the HOME Study, in Ohio, US (Spanier et al., 2012 (Spanier et al., , 2014a . Two cross-sectional studies used data from the biennial National Health and Nutrition Examination Survey (NHANES); one was limited to children ages 6-19 (Spanier et al., 2014b) and the other combined children (6 years and older) and adults (total sampled population mean age of 38.8 years) (Vaidya and Kulkarni, 2012) .
Various aspects of respiratory health were assessed. The endpoint of interest in the Donohue et al. (2013) study included reported wheeze and asthma, as well as laboratory data on seroatopy, fractional exhaled nitric oxide (FeNO) and IgE concentrations in children up to 12 years of age. Spanier et al. (2012) focused on wheeze in children up to three years of age and in a follow-up study examined parent-reported wheeze every six months for five years and forced expiratory volume in 1 s (FEV 1 ) at four and five years of age (Spanier et al., 2014a) . In an analysis of two NHANES surveys (2007) (2008) (2009) (2010) , Spanier et al. (2014a Spanier et al. ( , 2014b evaluated lung function using data on FEV 1 , forced vital capacity (FVC), forced expiratory flow, 25%-75% (FEF 25-75 ), FEV 1 /FVC ratio, and FeNO in children 6-19 years old. Vaidya and Kulkarni (2012) assessed asthma in participants 6 years and older using data on ever-asthma questions, outcome of asthma attack questions, differential eosinophil count, total serum IgE, and atopy (presence of one or more allergenspecific IgE in excess of 0.35 kU/L).
BPA exposure in all five studies was assessed using total urinary BPA, but urine samples were collected at different times and different methods of adjusting for sample dilution were used. In the HOME study (Spanier et al., 2012 (Spanier et al., , 2014a , maternal spot urine samples were collected and measured for BPA at~16 and 26 weeks of gestation and at birth. In the Columbia study (Donohue et al., 2013) , BPA was measured in spot urine samples collected during the third trimester and from children at 3, 5 and 7 years. In NHANES (Spanier et al., 2014b; Vaidya and Kulkarni, 2012) , one spot urine sample per participant was measured for BPA.
Only Spanier et al. (2014a) used creatinine-adjusted individual BPA concentrations. Spanier et al. (2014b) included creatinine as a covariate in their models, Donohue et al. (2013) used specific gravity-adjusted urinary BPA and Vaidya and Kulkarni (2012) made no adjustments for urine dilution.
Neurodevelopment literature and use of BEES-C
The five co-authors of this paper independently reviewed each of the seven publications on BPA exposure and neurodevelopment and used the BEES-C instrument (Table 2) to assess the 14 elements of study quality. The results of these reviews are shown in Tables 3-9. We describe here the results of these reviews for each of the elements of the NA = not applicable. instrument in terms of concordance among reviewers. The degree of concordance or discordance among the reviewers for each assessment component is illustrated in Table 10 . Changes to BEES criteria were proposed for three of six elements that showed discordance across reviewers, namely biomarker stability, sample contamination and study rationale. The other elements (study participants, data analysis and data reporting) related to General Epidemiologic Study Design Considerations and were considered elements that require a high degree of professional judgment, allowing for differences in opinion and interpretation across reviewers. For this reason, we advise reviewers to provide full justification of their assessment.
Because BEES-C does not require strict quantitative cut-offs between tiers, for each element some inter-reviewer variability is expected between adjacent tiers. We also evaluate whether each element is functional in its current form or requires modification to improve its utility. Note that open cells (no color) with a diagonal line indicate that a reviewer chose not to assess a specific element. Not all reviewers will have the necessary expertise to assess study quality for all elements in the BEES-C instrument. It is preferable for reviewers to tier the elements for which best professional judgment can be used.
Biological relevance/exposure biomarker
The intent of this element is to assess whether the biomarker has an accurate and precise quantitative relationship with external exposure, internal dose or target dose. As all seven papers used total urinary BPA as the exposure biomarker, it is expected that each reviewer would be consistent in assigning the studies to the same tier. As expected, most placed the publications in the highest quality tier (Tier 1) as total urinary BPA is considered to have an accurate quantitative relationship with external exposure. However, one reviewer selected Tier 2 for this element because urinary BPA does not reflect the biologically relevant (unconjugated) concentration. Because the element includes assessments of both biomarkers of exposure and biomarkers of effect, it is important for reviewers to clearly distinguish whether they are describing the biomarker of exposure or effect when tiering and providing the rationale for the tiering decision.
Biological relevance/effect biomarker
The element explores the value of the biomarker for its relationship with a health outcome. BPA is not a biomarker of effect and so almost all reviewers either noted that this element is not applicable to this body of literature or left the element blank. One reviewer categorized this element as Tier 2, noting the limited animal data on BPA mechanism(s) of action for neurodevelopmental effects. According to the reviewers, this element provided sufficient guidance for assessing biomarker of effect quality, although we recommend that this be revisited using literature on a different biomarker.
Specificity
Studies using biomarkers that are specific to one parent compound or to multiple parent compounds with similar effects will yield more robust information on exposure/outcome relationships. Because total BPA is derived from one parent compound, most reviewers placed all of the publications in Tier 1 for this element. Tier 2 categorization was selected by one reviewer, noting that the use of urinary BPA, which measures both the free and conjugated BPA, includes both biologically active and inactive compounds. The element as currently written is therefore ambiguous as to whether it refers to the biomarker(s) or the parent compound(s). We are proposing a modification to original Tier 2 language (Table 2) as follows: Biomarker is specific for exposure to more than one parent compound and is related to mode of action of the mixture.
Method sensitivity
With this element, the instrument seeks to capture whether there is a sufficient percentage of the measurements above the limit of detection to enable a reasonable assessment of exposure/outcome relationships. Because the methods for measurement of urinary BPA are wellestablished and BPA was measurable in a large percentage of the study populations, reviewers were generally consistent in assigning publications to Tier 1 for this element. However, one publication was categorized as Tier 2 because the percent detected was not given. We recommend reassessing this element using literature on a different biomarker that is more difficult to measure. This may help better define what constitutes a "sufficient" percentage of measures above the limit of detection.
Biomarker stability
Samples of human fluids and tissues are often stored for long periods of time and may be subject to numerous full or partial freeze/thaw cycles, potentially resulting in biomarker degradation. The ideal study would therefore store samples for a period of time for which stability is demonstrated, and storage history is well-documented. More generally, stability data are essential to assessing data quality and should be published for different storage conditions by the laboratories involved in these analyses. In evaluating the seven publications for this element, reviewers were generally in agreement that two key issues resulted in either Tier 2 or Tier 3 categorization: first, most papers did not provide information on storage times (i.e., no documentation) and second, for studies that did provide storage time information, samples were often stored for longer than 30 months, which is longer than the period over which BPA stability has been demonstrated ). This element is considered of high importance for chemicals with short half-lives and is a study component that is often not given sufficient consideration. To improve clarity of the instrument, we recommend modifying the language for Tier 3 (Table 2) to read: Samples with either unknown storage history and/or no stability data for target analytes.
Sample contamination
Contamination in the field and/or the laboratory has been shown to affect research that uses human or animal tissue samples; precautions must be taken to avoid or at least minimize this problem (Calafat and Needham, 2009 ). This BEES-C element is of considerable importance NA = not applicable. 6 (continued) in assessing the quality of studies of short-lived chemicals such as BPA, which are ubiquitous in the environment and the laboratory and are often components of sampling and laboratory equipment. The reviewers were generally in agreement that the publications fell into either Tier 2 or 3 due to lack of documentation demonstrating avoidance of sample contamination. The key ambiguity with this element pertains to the distinction between not using proper QC procedures and possibly usingbut not documentingthe procedures. We suggest the following modification to Tier 2 (Table 2) : Incomplete documentation of QC steps taken to avoid contamination. Table 7 BEES-C assessment of Miodovnik et al. (2011) (diagonal line through cell indicates element not assessed by that reviewer).
Method requirements
The most reliable biomarker measurements are obtained using instrumentation that can unambiguously identify and quantify the analyte of interest. The state-of-the-science instrument for measuring BPA is high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) (Ye et al., 2005) ; all seven publications used this methodology. Thus, all received a Tier 1 categorization. Although reviewers raised no issues regarding application of this element in the current assessment, we recommend that this be revisited using biomarkers measured using differing analytical methods.
Matrix adjustment
Evidence from multiple studies indicates that exposure/outcome relationships are affected by the method(s) used for matrix adjustment (Goodman et al., 2014) . As the optimal method of matrix adjustment remains a matter of scientific debate, this BEES-C element addresses the issue by favoring studies with increased transparency, i.e., studies that provide information using adjusted and unadjusted measures, thereby permitting the reader to draw conclusions from a more complete set of results. There was concordance among reviewers for three of the seven publications reviewed here (Braun et al., 2009 (Braun et al., , 2011 Hong et al., 2013) . In Braun et al. (2009 Braun et al. ( , 2011 , all measures were adjusted for dilution using creatinine and no unadjusted results were given (Tier 2), whereas Hong et al. also conducted analyses with unadjusted urinary BPA and with creatinine as a covariate in the model (results for this latter analysis were noted but not shown) (Tier 1). The remaining studies (Tables 5 and 7-9) yielded discordant reviews, with a mix of Tier 1 and 2 categorizations. These studies either conducted analyses with both adjusted and unadjusted urinary BPA and only provided results for one of the methods, or used only unadjusted urinary BPA measures but included creatinine in the model as a covariate. The reviewers interpreted the tiering criteria differently in these situations. We suggest the following modification to Tier 1 (Table 1) to improve clarity: Study provides results either in the main publication or as a supplement for creatinine-adjusted or SG-adjusted and non-adjusted urine concentrations and reasons are given for adjustment approach.
Temporality
This element is critical for studies addressing the causal hypotheses about exposure/outcome relationships. In general, cross-sectional studies of short-lived biomarkers will be designated as Tier 3 studies whereas prospective longitudinal studies will be either Tier 1 or 2. Distinguishing between Tiers 1 and 2 requires an understanding of critical windows of exposure, and for most chemicals where the critical window is not known this will present the reviewer with ambiguity. For the seven publications reviewed here, reviewers were in agreement for the two studies by Braun et al. (2009 Braun et al. ( , 2011 , Hong et al. (2013) , and Yolton et al. (2011) . Harley et al. (2013) , Miodovnik et al. (2011) and Perera et al. (2012) were given a mix of Tier 1 and Tier 2 designations. In general, the studies that obtained urinary BPA measurements during gestation and childhood and examined children's neurodevelopment were most commonly categorized as Tier 1. The cross-sectional study (Hong et al., 2013) was categorized as Tier 3 by all reviewers. Based on the present review, this element provided sufficient guidance for assessing quality in terms of temporality.
Exposure variability and misclassification
This element in the BEES-C instrument is essential to evaluating relationships between exposure to short-lived chemicals and health outcomes, especially for chronic diseases. Intra-individual variability in biological levels of short-lived chemicals has been demonstrated for numerous chemicals, including BPA (LaKind et al., 2014a; Townsend et al., 2013) , phthalates (Fromme et al., 2007; Goodman et al., 2014) , pesticides (Wielgomas, 2013) and triclosan (Meeker et al., 2013) . If variability is random, the observed association is expected to be attenuated; if, however, the exposure measurement error is systematic, the resulting magnitude and direction of bias may be more difficult to ascertain. Because analyses of short-lived chemicals in a single sample are particularly susceptible to exposure measurement error, studies relying on one measure of exposure are assigned to Tier 3. However, as was noted in the publications reviewed here, studies may collect more than one exposure measure but still not be considered Tier 1 if each measure was used independently. In general, the reviews for this element revealed selections of different adjacent Tiers that are likely due to differences in professional judgment. For example, assessment of exposure variability and misclassification of Braun et al. (2011) yielded a mix of Tier 1 and Tier 2 categorizations, as more than one sample per person was collected and variability was discussed; however, variability was not addressed quantitatively and reviewers had differing opinions on appropriate categorization. We do not recommend any changes to the element at this time.
Study rationale
After using the instrument to evaluate the body of literature described here, it became apparent that critical aspects of study rationale are addressed elsewhere by BEES-C. For example, it is crucial that studies designed for a different research objective (using previouslycollected samples for a past study or earlier phase of a study) evaluate whether the collection, storage and analysis methods would mitigate possible contamination for the current target chemical(s). In addition, the samples should have been collected during an exposure window that is most relevant to the outcome of interest and the sampling design NA = not applicable. should have considered issues of exposure misclassification. Further, issues related to multiple comparisons can arise depending on the study rationale/design and must be addressed. All of these considerations, however, are dealt with in other BEES-C elements. We therefore recommend removing this element from the instrument. Despite these issues, it is worth noting that there was high concordance across reviewers for this element. Only one study included reviews that included Tier 1 and Tier 3. Table 8 BEES-C assessment of Perera et al. (2012) (diagonal line through cell indicates element not assessed by that reviewer).
Study participants
This BEES-C element addresses the recruitment procedure and response rate and as such is not specific to biomonitoring studies but remains an important consideration in assessing overall study quality. It is essential that the study include a careful description of the recruitment protocol, characteristics of the study population and inclusion/ exclusion criteria. The element does not include quantitative guidance for reviewers (e.g., there is no numerical cut-off for categorizing study response rate). Six of the seven studies were classified as either Tier 1 or 2. In a single case, a reviewer placed a study in Tier 3 when other reviewers classified the studies as either Tier 1 or 2 (review of Harley et al.) . We do not recommend any changes to the element.
Data analysis
Although this element is not specific to biomonitoring of short-lived chemicals, it is essential in evaluating study quality. Assessments of this element for Hong et al. (2013) and Miodovnik et al. (2011) were highly discordant and reviewers only achieved complete concordance for Braun et al. (2009) and Harley et al. (2013) . This is likely because assessment of this element is largely a matter of professional judgment. For example, there will likely be differences of opinion regarding whether each study included "adequate consideration of extraneous factors." A review of control variables in different studies shown in Table 1 reveals substantial differences in number and type of variables. Despite variability, this element will provide valuable information if reviewers take time to justify their evaluations, especially as they pertain to overlooked control variables or other critical aspects of data analysis. For example, diet and breastfeeding are associated with both neurodevelopment and BPA exposure but these factors have not been considered in the extant literature. No changes to the element are recommended.
Reporting
This element covers three main issues related to reporting of study results: transparency, multiple testing and reporting bias. The reviewer assessments ranged from completely concordant to highly discordant. We do not recommend any changes, but emphasize that the reviewers should provide full justification of their assessment.
Summary
Use of the BEES-C instrument to examine the epidemiology literature on BPA and neurodevelopmental outcomes revealed similar issues to those found for BPA and obesity, diabetes and heart disease (LaKind et al., 2014a) . The majority of the studies are hindered by lack of information on biomarker stability, potential for sample contamination and biomarker concentration variability within and between individuals that could lead to misclassification of exposure.
Respiratory health literature quality assessment
Using the BEES-C, we conducted an assessment of the literature on BPA and respiratory health. The review used the same approaches and summarized the results in the same format as that for neurodevelopment. Similar assessments of inter-reviewer concordance/discordance (Table 10 and tables in Appendix A) and recommendations for modifications of the BEES-C arose with this literature. As with the health outcomes discussed above, use of the BEES-C instrument to examine the epidemiology literature on BPA and respiratory effects revealed that the majority of the studies are hindered by exposure assessments that are likely to result in exposure misclassification.
Discussion
Systematic evaluative tools have been developed for various types of research (general issues in STROBE [Vandenbroucke et al., 2007] and CONSORT [Moher et al., 2001] , genetic studies in STREGA [Little et al., 2009] , comparative treatment effectiveness research in GRADE [Owens et al., 2010] , studies of diagnostic accuracy in STARD [Bossuyt et al., 2004] , risk of bias assessment tools [OHAT, 2015; Sterne et al., 2014; Woodruff and Sutton, 2014; Viswanathan et al., 2012] , and neurodevelopmental function testing in HONEES [Youngstrom et al. 2011] ), but BEES-C is the first systematic guidance on best practices for environmental epidemiologic research that incorporates biomonitored measures of short-lived chemicals. Short-lived chemicals in environmental epidemiology present special challenges due to complexities associated with determining the appropriate number of samples and timing of collection to best characterize exposure and capture relevant windows of exposure, and the ubiquity of short-lived chemicals which introduces difficulties in avoiding sample contamination. Further, in these studies, researchers often measure a large number of chemicals in one sample, highlighting the importance of full reporting (LaKind et al., 2014b) .
In the present test application of the BEES-C instrument, we focused on a single chemical, and for this reason certain aspects of the evaluation were the same across all studies. However, the publications included in this review used different cohorts, methodological approaches and designs, and provided a range of study aspects which could be evaluated independently.
Based on this first use of the BEES-C instrument, we found that most of the BEES-C elements provided clear guidance. We recommend slight modifications to the tiering language for four of the elements (specificity, biomarker stability, sample contamination, matrix adjustment) as described above. We further recommend removing the element on study rationale.
In addition to the specific recommended modifications to the BEES-C elements, there were general lessons learned from this assessment. NA = not applicable. First, it is our belief that this type of review cannot and should not be conducted by a single individual. Rather, this is a team exercise requiring several areas of expertise, including exposure assessment, epidemiology and analytical chemistry. Because professional judgment will always be a part of a study review, discrepancies across reviewers should be expected. In particular, based on our experience, selection of adjacent Tiers will be common. When there is greater discordance, i.e. selection across all Tiers, it is important that the justifications for the selections be reviewed to assess whether the differences identified would adversely impact on the proposed use of the study data. While we attempted to reduce the ambiguities in the instrument language, we expect that further uses of the BEES-C will lead to additional modifications to the instrument.
Second, as noted previously (LaKind et al., 2014b), we are not aware of publications that would be considered Tier 1 for all evaluative aspects; most studies would contain at least some elements assessed as Tier 2 or 3. This does not necessarily present an insurmountable problem in terms of WOE assessment. However, there are certain Tier 3 designations that would result in a study of low utility (LaKind et al., 2014b) . For example, sample contamination or lack of sample stability would impede proper interpretation of the results.
Third, in our assessment of the BPA/neurodevelopmental literature, we found that studies using samples previously collected and stored for another purpose (e.g., earlier research by the same team but testing a different hypothesis) were often categorized as Tier 2 or 3 for many elements of BEES-C. For studies using previously obtained samples, researchers will need to describe the quality of the archived samples in terms of stability and lack of contamination in order to demonstrate that the measurements represent high quality data.
In summary, we found that most elements of the BEES-C instrument were effective in evaluating the quality of the available studies, with reviews generally concordant and justifications consistent. However, we also noted that certain elements could be improved in terms of clarity of wording and consistency of tiering recommendations. In addition, based on the current application of the instrument, we concluded that one of the elements (study rationale) appears redundant and should be removed.
We recommend that the modified BEES-C instrument be used to assess study quality for environmental epidemiologic research using biomonitored measures of short-lived chemicals. The instrument can be used alone or in conjunction with already-existing evaluative tools for peer review of proposals and manuscripts, and for assessing study quality as part of WOE assessments. It can further be used to advance the understanding of a particular research question by highlighting methodological limitations of the existing literature and by identifying knowledge gaps. With slight modifications, the BEES-C instrument would also be applicable to persistent biomonitored chemicals. Table 10 Degree of inter-reviewer concordance/discordance by BEES-C element for studies on BPA and neurodevelopment and respiratory effects. Concordance occurs when all reviewers select the same tier for a given BEES-C element or select at most two neighboring tiers (e.g., Tier 1 and Tier 2). Discordance occurs when three tiers were selected by reviewers for a given element or when two non-neighboring tiers were selected (Tier 1 and Tier 3). Discordance across reviews occurred either because the BEES-C guidance required modification to improve clarity or because the element includes a high degree of professional judgment, allowing for differences in opinion an interpretation across reviewers.
Neurodevelopmental/BPA literature Respiratory effects/BPA literature
BEES-C element All reviewers agree
Only one-tier difference across reviews
Reviews span across three tiers
All reviewers agree
Reviews span across three tiers (continued on next page) (continued on next page) (continued on next page) (continued on next page) (continued on next page)
